英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
Selonsertib
|
1448428-04-3 |
SELONSERTIB
|
Selonsertib;GS-4997;ASK-1;司隆色替;瑟隆舍替;司隆色替;瑟隆舍替;GS4997;GS4997;司隆色替;瑟隆舍替;GS4997;GS 4997
|
C24H24FN7O |
445.4920632 | |
(±)-Huperazine A
|
120786-18-7 |
石杉碱甲
|
(11E)-5-氨基-11-亚乙基-5,6,9,10-四氢-7-甲基-5,9-甲基环八[B]吡啶-2(1H)-;卷柏石松鹼;石杉碱甲;(±)-石杉碱甲A;卷柏石松;卷柏石松碱;石杉碱甲;(卤)-HUPERZINE A
|
C15H18N2O |
242.32 | 600-320-6 |
CJ-023423
|
415903-37-6 |
GRAPIPRANT
|
CJ-023423;CJ 023423;CJ023423;CAS#415903-37-6;RQ-00000007;RQ 00000007;RQ00000007;AAT-007;AAT007;AAT 007;GRAPIPRANT;GRAPIPRANT;RQ-00000007;AAT-007;CS-1556
|
C26H29N5O3S |
491.60516 | |
LLY507
|
1793053-37-8 |
LLY-507
|
CS-2196;5-氰基-2'-[4-[2-(3-甲基-1H-吲哚-1-基)乙基]-1-哌嗪基]-N-[3-(1-吡咯烷基)丙基]-[1,1'-联苯]-3-甲酰胺;LLY-507;LLY507;LLY 507
|
C36H42N6O |
574.75828 | |
(±)-Lauroylcarnitine chloride
|
7023-03-2 |
LAUROYL L-CARNITINE;C12 CARNITINE
|
LAUROYL L-CARNITINE;C12 CARNITINE
|
C19H37NO4 |
343.5 | |
4-(Hydroxymethyl)phenoxyacetic acid
|
68858-21-9 |
4-(羟基甲基)苯氧基乙酸
|
4-羟甲基苯氧乙酸,对羟甲基苯氧乙酸;P-羟甲基苯氧乙酸;HMP LINKER;对羟甲基苯氧乙酸;4-(羟基甲基)苯氧基乙酸;4-(羟基甲基)苯氧基乙酸,98%;4-(羟甲基)苯氧乙酸;4-羟甲基苯氧基乙酸
|
C9H10O4 |
182.17 | 677-017-0 |
VERRUCULOGEN
|
12771-72-1 |
震颤真菌毒素
|
疣孢青霉原;疣孢青霉原;疣孢青霉原 TR 1;震颤真菌毒素(>98%,BC);震颤真菌毒素,来源于青霉菌;震颤真菌毒素
|
C27H35N3O7 |
513.58 | 634-189-1 |
Oxethazaine
|
126-27-2 |
奥昔卡因
|
2-双(N-甲基-N-苯基叔丁基-氨基甲酰甲基)氨基乙醇;阿塞赛因;奥西卡因;羟乙卡因;3-羟乙基亚氨基双(N-[Α,Α-二甲基苯乙基]-N-甲基乙酰胺);奥昔卡因
|
C28H41N3O3 |
467.64344 | 204-780-5 |
Cabergoline
|
81409-90-7 |
卡麦角林
|
(8Β)-N-[3+(二甲氨基)丙基]-N-[(乙氨基)羧基]-6-(2-丙烯基)麦角林-8-羧酰胺;-烯丙基-N-[3-(二甲基氨基)丙基]-N-(乙基氨基甲酰基)麦角林-8-甲酰胺;卡麦角林杂质;6-烯丙基-N-[3-(二甲基氨基)丙基]-N-(乙基氨基甲酰基)麦角林-9-甲酰胺;卡麦角林
|
C26H37N5O2 |
451.6 | 200-419-0 |
RI-2
|
1417162-36-7 |
RI-2
|
CS-1675;1-(3,4-二氯苯基)-3-(4-甲氧基苯基)-4-(4-吗啉基)-1H-吡咯-2,5-二酮;RI2;RI 2
|
C21H18Cl2N2O4 |
433.28462 | |
EPZ015666
|
1616391-65-1 |
EPZ015666
|
EPZ-015666;EPZ 015666;GSK3235025;EPZ-015666;EPZ 015666;N-[(2S)-3-(3,4-二氢-2(1H)-异喹啉基)-2-羟基丙基]-6-(3-氧杂环丁基氨基)-4-嘧啶甲酰胺
|
C20H25N5O3 |
383.4442 | |
SEP-0372814
|
1516895-53-6 |
SEP-0372814
|
CS-1706;SEP 0372814;SEP0372814;REL-2-[(1R,2R)-2-(5,8-二甲基[1,2,4]三唑并[1,5-A]吡嗪-2-基)环丙基]-3-甲基咪唑并[2,1-F][1,6]萘啶
|
C21H19N7 |
369.42246 | |
TH588
|
1609960-31-7 |
TH588
|
CS-1701;TH588>98%;TH 588;TH-588;TH588;N4-环丙基-6-(2,3-二氯苯基)-2,4-嘧啶二胺
|
C13H12Cl2N4 |
295.16718 | |
LDC1267
|
1361030-48-9 |
LDC1267
|
CS-1641;LDC 1267;LDC-1267;N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]-3-氟苯基]-4-乙氧基-1-(4-氟-2-甲基苯基)-1H-吡唑-3-甲酰胺
|
C30H26F2N4O5 |
560.5480464 | |
KN-93 Phosphate
|
1188890-41-6 |
KN-93PHOSPHATE
|
KN 93;KN93;CS-1902;KN93磷酸盐
|
C26H32ClN2O8PS |
599.032641 | |
THZ1
|
1604810-83-4 |
THZ1
|
CDK7 inhibitor;THZ1;THZ1, CDK7 inhibitor;THZ1 ?N-{4-[5-Chloro-4-(1H-indol-3-yl)-pyrimidin-2-ylamino]-phenyl}-4-(4-dimethylamino-but-2-enoylamino)-benzamide;(E)-N-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-enamido)benzamide THZ1;N-[3-[[5-Chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-4-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]benzamide;THZ1 free base;(E)-N-(3-((5-Chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(4-(dimethylamino)but-2-en
|
|||
PTC-209
|
315704-66-6 |
PTC-209
|
CS-1315;N-(2,6-二溴-4-甲氧基苯基)-4-(2-甲基咪唑并[1,2-A]嘧啶-3-基)-2-噻唑胺;2-THIAZOLAMINE,N-(2,6-DIBROMO-4-METHOXYPHENYL)-4-(2-METHYLIMIDAZO[1,2-A]PYRIMIDIN-3-YL)-
|
C17H13Br2N5OS |
495.19102 | 808-910-7 |
Alvelestat
|
848141-11-7 |
ALVELESTAT
|
AZD9668;AZD-9668;AZD 9668;CS-1060
|
C25H22F3N5O4S |
545.5334896 | |
P 22077
|
1247819-59-5 |
P 22077
|
P 22077;P-22077;1-[5-[(2,4-二氟苯基(硫基]-4-硝基-2-噻吩基]乙酮;CS-1115
|
C12H7F2NO3S2 |
315.315686 | |
TPT-260 Di hydrochloride
|
2076-91-7 |
NSC 55712
|
THIOPHENE-2,5-DIYLBIS(METHYLENE)DICARBAMIMIDOTHIOATE.2HCL;硫代氨基亚胺酸2,5-噻吩二基二(亚甲基)二酯二盐酸盐;NSC55712;TPT260 DIHYDROCHLORIDE;TPT 260 DIHYDROCHLORIDE;TPU-260 DIHYDROCHLORIDE;NSC-55712;NSC 55712
|
C8H14Cl2N4S3 |
333.32456 |